Table: q1_q4_2019_prescription_drugs_intro_to_market , manufacturer_name like E*

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  *

manufacturer_name	ndc_number	drug_product_description	date_introduced_to_market	wac_at_introduction	marketing_pricing_plan_description	marketing_pricing_plan_non_public_indicator	estimated_number_of_patients	breakthrough_therapy_indicator	priority_review_indicator	acquisition_date	acquisition_price	acquisition_price_non_public_indicator	acquisition_price_comment	general_comments	supporting_documents
EMD Serono, Inc.	44087040004	Mavenclad (cladribine) 10 mg per tablet (4)	2019-04-02	28428.5600	None	1	None	None	None	None	None	None	None	This information is applicable to all submitted Mavenclad NDCs. Mavenclad was approved for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. According to the National Multiple Sclerosis Society, MS is believed to affect nearly 1 million adults over the age of 18 in the United States. Approximately 85% of people with MS are initially diagnosed with relapsing-remitting MS. (www.nationalmssociety.org)	None
EMD Serono, Inc.	44087040005	Mavenclad (cladribine) 10 mg per tablet (5)	2019-04-02	35535.7000	None	1	None	None	None	None	None	None	None	This information is applicable to all submitted Mavenclad NDCs. Mavenclad was approved for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. According to the National Multiple Sclerosis Society, MS is believed to affect nearly 1 million adults over the age of 18 in the United States. Approximately 85% of people with MS are initially diagnosed with relapsing-remitting MS. (www.nationalmssociety.org)	None
EMD Serono, Inc.	44087040006	Mavenclad (cladribine) 10 mg per tablet (6)	2019-04-02	42642.8400	None	1	None	None	None	None	None	None	None	This information is applicable to all submitted Mavenclad NDCs. Mavenclad was approved for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. According to the National Multiple Sclerosis Society, MS is believed to affect nearly 1 million adults over the age of 18 in the United States. Approximately 85% of people with MS are initially diagnosed with relapsing-remitting MS. (www.nationalmssociety.org)	None
EMD Serono, Inc.	44087040007	Mavenclad (cladribine) 10 mg per tablet (7)	2019-04-02	49749.9800	None	1	None	None	None	None	None	None	None	This information is applicable to all submitted Mavenclad NDCs. Mavenclad was approved for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. According to the National Multiple Sclerosis Society, MS is believed to affect nearly 1 million adults over the age of 18 in the United States. Approximately 85% of people with MS are initially diagnosed with relapsing-remitting MS. (www.nationalmssociety.org)	None
EMD Serono, Inc.	44087040008	Mavenclad (cladribine) 10 mg per tablet (8)	2019-04-02	56857.1200	None	1	None	None	None	None	None	None	None	This information is applicable to all submitted Mavenclad NDCs. Mavenclad was approved for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. According to the National Multiple Sclerosis Society, MS is believed to affect nearly 1 million adults over the age of 18 in the United States. Approximately 85% of people with MS are initially diagnosed with relapsing-remitting MS. (www.nationalmssociety.org)	None
EMD Serono, Inc.	44087040009	Mavenclad (cladribine) 10 mg per tablet (9)	2019-04-02	63964.2600	None	1	None	None	None	None	None	None	None	This information is applicable to all submitted Mavenclad NDCs. Mavenclad was approved for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. According to the National Multiple Sclerosis Society, MS is believed to affect nearly 1 million adults over the age of 18 in the United States. Approximately 85% of people with MS are initially diagnosed with relapsing-remitting MS. (www.nationalmssociety.org)	None
EMD Serono, Inc.	44087040010	Mavenclad (cladribine) 10 mg per tablet (10)	2019-04-02	71071.4000	None	1	None	None	None	None	None	None	None	This information is applicable to all submitted Mavenclad NDCs. Mavenclad was approved for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. According to the National Multiple Sclerosis Society, MS is believed to affect nearly 1 million adults over the age of 18 in the United States. Approximately 85% of people with MS are initially diagnosed with relapsing-remitting MS. (www.nationalmssociety.org)	None
EMD Serono, Inc.	44087353501	Bavencio (avelumab) Injection	2019-05-14	1572.7000	None	1	None	1	1	None	None	None	None	The monthly estimated patient total is internal information that is aspirational, is not publicly available, and is subject to market adoption. BAVENCIO was approved in combination with axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). According to the American Cancer Society, about 73,820 new cases of kidney cancer will occur in the United States in 2019 (https://www.cancer.org/cancer/kidney-cancer/about/key-statistics.html, last visited June 12, 2019). Approximately 90% of kidney cancers are renal cell carcinomas (https://www.cancer.org/cancer/kidney-cancer/about/what-is-kidney-cancer.html, last visited June 12, 2019). Approximately 30% of RCC patients are first diagnosed with RCC at the advanced stage (https://seer.cancer.gov/statfacts/html/kidrp.html, last visited June 12, 2019).	None
Epic Pharma	42806005030	Meperidine Hcl 50mg 30 Tab Epic	2019-12-30	783.0000	None	1	None	None	None	None	None	None	None	lauching new size-30 count Epic Pharma developed the drugs	None